Nu-Med Plus, Inc. Advances Blood and Plasma Transfusion Technology with New Patent
November 14 2018 - 12:07PM
Nu-Med Plus’ Proprietary Technology Aims
to Increase Longevity and Safety of Banked Blood Supply and Reduce
Side Effects of Blood Transfusions
SALT LAKE CITY, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus,
Inc. (OTCQB: NUMD), a medical device leader developing new nitric
oxide delivery technology, announces a patent application on the
new device which is designed to pretreat stored blood products with
nitric oxide prior to patient transfusions.
Nitric oxide is naturally occurring in blood and acts as a
vasodilator by expanding and dilating blood vessels. According to
recent studies1, the longer blood is stored, the more
nitric oxide is depleted, increasing potential risks to patients
such as hypoxia, infection, and heart failure. The same
studies2 suggest pretreating stored blood products with
nitric oxide prior to a transfusion increases the ability of donor
blood to carry and transfer oxygen when transfused into a
patient.
Nu-Med Plus’ patent describes the new technology as a simple
nitric oxide infusion device that can be used during or post blood
collection. More than four million Americans receive blood
transfusions every year; of those, more than 300,000 patients in
the United States receive one or more blood units that have been
stored for more than 30 days. The Federal Drug Administration
current does not allow blood stored for more than 42 days to be
used in transfusions.
“A blood transfusion is one of the most common medical
procedures in the world and we believe this new Nu-Med Plus nitric
oxide delivery technology will decrease the risks and increase the
life-saving potential of blood transfusions,” said Jeff Robins, CEO
of Nu-Med Plus. “This new application of the Nu-Med Plus’
technology also offers the potential to extend storage of blood
beyond its current time limits.”
With this new device, Nu-Med Plus will now seek enrollment in
further studies to investigate its efficacy. Nu-Med Plus is
currently in the process of FDA approval for three additional
nitric oxide delivery units including a fixed hospital unit,
clinical unit, and a portable unit. Nu-Med Plus’ technology is
designed to be utilized for a variety of inhaled nitric oxide
treatments. Inhaled nitric oxide has already been proven to
stabilize blood pressure, open airways, fight infections and blood
clots, combat aging and treat erectile dysfunction.
Media Contact: eric@s2spr.com
1 Source 2 Source
About Nu-Med Plus, Inc.: Nu-Med Plus, Inc.
founded in 2011, is a medical device development company created to
explore medical applications of newly developed nitric oxide
technologies. The strategy focuses on high growth potential markets
where there is a clearly defined need recognized by the medical
community that can be addressed by Nu-Med Plus and its technical
expertise. Initial research and product development has been in the
delivery of inhaled nitric oxide gas for therapeutic use. For more
information please visit www.nu-medplus.com. Follow Nu-Med Plus on
Twitter and LinkedIn for the latest news.
Forward-Looking Statements: Information set
forth in this news release contains forward-looking statements that
are based on assumptions as of the date of this news release. These
statements reflect management's current estimates, beliefs,
intentions and expectations. They are not guarantees of future
performance. The Company cautions that all forward-looking
statements are inherently uncertain, and that actual performance
may be affected by a number of material factors, many of which are
beyond the Company's control. Such factors include, among other
things: risks and uncertainties relating to the Company's ability
to complete proposed private placement financing. Accordingly,
actual and future events, conditions and results may differ
materially from the estimates, beliefs, intentions and expectations
expressed or implied in the forward-looking information. Except as
required under applicable securities legislation, the Company
undertakes no obligation to publicly update or revise
forward-looking information.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/4ca06ae7-68d0-47fd-b723-fc71a65ac9f3
Nu Med Plus (QB) (USOTC:NUMD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nu Med Plus (QB) (USOTC:NUMD)
Historical Stock Chart
From Dec 2023 to Dec 2024
